Introduction
Ancrod and batroxobin are both thrombin-like snake venom serine proteases produced by Calloselasma rhodostoma and Bothrops atrox moojeni, respectively. Details of the mechanism of fibrinogen binding and action have been published for batroxobin [1] and ancrod [2] . Because ancrod and batroxobin produce fibrin that is readily degraded they promote fibrinogen depletion and have been investigated as potential treatments to reduce normal clot formation under various circumstances. Both enzymes have been investigated as treatments for ischemic stroke; however, clinical trials over several decades have shown mixed results [3, 4] . Ancrod has other indications and is currently in clinical trials for treatment of sudden sensorineural hearing loss (SSHL). Because batroxobin is insensitive to plasma inhibitors, it has found uses in clinical laboratories as a diagnostic reagent to measure batroxobin clotting time (Reptilase time) [5] , which is useful when plasma samples contain heparin for example. Many batroxobin products are available globally under a variety of brand names, for example Reptilase, Hemocoagulase and Defibrase. Efforts to standardize batroxobin activity at NIBSC began in 1978 with the establishment of the 1st British Standard (BS), 75/527. The original unit was based on the plasma clotting unit (PCU), where 2 PCU were defined as 'the amount of enzyme in 0.1 mL which clots 0.3 ml of citrated plasma in 19 AE 0.2 s'. The 2nd BS was calibrated against the 1st BS [7] , but it was decided to develop a WHO Reference Reagent (RR) for batroxobin as a step towards making a WHO IS. The calibration of a candidate WHO RR for batroxobin and a candidate replacement WHO IS for ancrod were included in the same collaborative study.
Collaborative study

Materials
Bulk preparations of ancrod and batroxobin, harvested from snake venoms and donated by manufacturers, were diluted to approximately 55 IU mL À1 (ancrod) and 50 units mL À1 (batroxobin) in sodium phosphate buffer containing 5 mg mL À1 human albumin. For batroxobin the same formulation and freeze-drying methods as used for the 2nd British Standard, 93/526, were employed as far as possible. Both reference materials were dispensed in 1-mL aliquots into 5 mL DIN ampoules before lyophilization following WHO guidelines [8] .
Predictions of the long-term stability from accelerated degradation studies indicate that ancrod (15/106) and batroxobin (15/140) are very stable, with no observed loss of potency after storage for 1 year at up to +20°C. Further time-points will be accumulated to generate a prediction for % loss of activity per year during storage at À20°C. Bench stability following reconstitution was also investigated and no evidence was found of significant loss of activity over 4 h of storage of solutions on ice.
Study
A total of 18 laboratories agreed to participate and of these 17 laboratories completed the study and returned results (see list in Acknowledgements). The aim of the study was to assign potency values to the candidate WHO 2nd IS for Ancrod (15/106) relative to the WHO 1st IS for ancrod (74/581), and to the candidate WHO RR for batroxobin (15/140) relative to the 2nd BS for batroxobin (93/526). Laboratories were encouraged to use their own assay method if available; however, guidance notes and example assay protocols were provided for three different types of clotting assays: using an automated coagulometer, a manual coagulometer or a turbidity assay using a 96-well microplate reader (for details see Supplementary Information S1). The guidance notes also contained instructions on dose ranges, replication and randomization of sample treatments to avoid systematic errors. Each laboratory was provided with ampoules for four assays and requested to return raw data to NIBSC for analysis. Laboratories used human plasma (13 participants) or fibrinogen (five participants) or both (laboratory 18). Potency estimates relative to the relevant reference standard were calculated by parallel line analysis with a log transformation of assay response. All calculations were performed using the software program Combistats [9] . Deviations from linearity and parallelism were considered significant at the 1% level (P < 0.01). Results from all valid assays were combined to generate unweighted geometric mean potencies for each laboratory and these laboratory means were used to calculate overall unweighted geometric mean potencies. Variability between assays and laboratories has been expressed using geometric coefficients of variation (GCV = (10 s -1) 9100%, where s is the standard deviation of the log 10 transformed potencies). The majority of assays gave valid estimates of relative potency. After a small number of exclusions for non-linearity or non-parallelism (4.5% of assays), potency estimates were calculated based on 63 independent assays for Sample A (ancrod) and 65 independent assays for Sample B (batroxobin), from 14 of the 18 laboratories that received samples. Sets of results from some laboratories were excluded where assay design was inadequate or data for samples were missing.
Results and discussion
Ancrod
An overall geometric mean potency for Sample A of 53.9 IU per ampoule, rounded to 54 IU per ampoule, was calculated using laboratory mean values, close to the expected potency of 55. The inter-laboratory GCV was low at 4.9%, and the intra-laboratory variation was also low, with all but two GCV values being less than 6%. Laboratory mean results presented in Fig. 1(A) appear to be randomly distributed with no particular pattern or bias for high or low potency estimates for any of the methods or substrates, shown as different colors.
Batroxobin
The overall geometric mean potency for the candidate WHO RR for batroxobin was 49.8 units per ampoule, which was rounded to 50 units per ampoule, the target potency. All but two laboratories had intra-laboratory GCVs at 6% or below and the inter-laboratory GCV was 11.6%, which is acceptable for this type of study. The spread of results and GCVs indicated more variability in results for batroxobin than was the case for ancrod. From the graph shown in Fig. 1(B) , there appears to be a significant difference in results obtained using fibrinogen compared with plasma as substrate, although this also overlaps with differences in methods as plate methods predominantly use fibrinogen as substrate. Although it is difficult to draw definitive conclusions from a relatively small number of datasets (17, from 15 different laboratories) covering five combinations of methods and substrates, these results do contrast with those returned for ancrod shown in Fig. 1(A) .
Additional independent assays at NIBSC comparing plasma and fibrinogen substrates using a manual coagulometer method confirmed an apparent 10% higher potency when using plasma as substrate compared with fibrinogen (data not shown). Thus, it seems to be the case that there is a small but significant discrepancy in activity between the 2nd BS for batroxobin, 93/526, and the candidate WHO RR, 15/140, that is observed when comparing fibrinogen and plasma as substrate, which is consistent in plate and coagulometer methods. Given the potential uses of batroxobin and history of standards, it is preferable to incorporate results using both plasma and fibrinogen as substrate as far as possible for value assignment in the current study and in future studies.
One possible explanation for the different behavior of batroxobin, 93/526, and the WHO RR, 15/140, with plasma or fibrinogen substrate, despite them being prepared in the same way, may be some deterioration of 93/ 526 over time. Accelerated degradation studies on 93/526 have demonstrated some loss of activity for samples stored at elevated temperatures since the manufacture of this standard in 1993, but these data could not be fitted to a simple model to predict long-term stability. Continuous monitoring of stability for 15/140 over the coming years will be important to guide future standardization strategies.
Comparisons with the thrombin IU
Thrombin was not included in the collaborative study; however, some additional microtiter plate-based assays using time to 50% clotting were performed that included the WHO 2nd IS for thrombin (01/580). Plasma could not be used as dose responses were non-linear or non-parallel. With fibrinogen, thrombin-equivalent IU per ampoule were 24 for ancrod (15/106) and 7.4 for batroxobin (15/140). Alternatively, the batroxobin unit is 15%, and ancrod IU is 44%, of the thrombin IU. These results are for information only. 
Conclusion
